We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Rebates and Biosimilar Approval Pathway Likely to Survive Healthcare Overhaul Conference
Drug Rebates and Biosimilar Approval Pathway Likely to Survive Healthcare Overhaul Conference
December 30, 2009
As Congress begins work on final healthcare legislation, creation of an approval pathway for biosimilars and increased drug rebates under Medicare Part D are among the measures most likely to survive.